藥物警訊 Singulair (montelukast) and All Montelukast Generics: Strengthened Boxed Warning - Due to Restricting Use for Allergic Rhinitis (2) [Posted 03/04/2020] AUDIENCE: Patient, Health Professional, Pharmacy, Allergy and Immunology Health Professionals should: • Ask patients about any history of psychiatric illness prior to initiating treatment. • Consider the risks and benefits of montelukast when deciding to prescribe or continue patients on the medicine. • Advise all patients of the risk of neuropsychiatric events when prescribing montelukast. Warnings about these side effects are included in the existing prescribing information. • Advise patients and parents/caregivers that the patient should stop taking montelukast and contact a health care professional immediately if changes in behavior or new neuropsychiatric symptoms, suicidal thoughts or behavior occur. • Monitor all patients treated with montelukast for neuropsychiatric symptoms. Events have occurred in patients with and without pre-existing psychiatric disease. Read more about the MedWatch Safety Alert, including a link to the FDA Drug Safety Communication, at: https://www.fda.gov/safety/medical-product-safety-information/singulair-montelukast-and-all-montelukast-generics-strengthened-boxed-warning-due-restricting-use?utm_campaign=FDA%20MedWatch%20Singulair%20%28montelukast%29%3A%20Strengthened%20Boxed%20Warning&utm_medium=email&utm_source=Eloqua 醫療專業人員應: • 開始治療前,請詢問病人是否有精神病相關病史。 • 在決定須新開立或繼續服用montelukast時,應考慮此藥的風險和益處。 • 仿單中已包含神經或精神相關副作用的警訊,處方montelukast時,應提醒所有病人注意相關副作用。 • 建議病人和家長/照顧者,若病人行為發生變化或出現新的神經精神相關症狀、自殺念頭或行為,應停止服用montelukast並立即聯繫醫療專業人員。 • 監測所有接受montelukast治療的病人有無神經精神相關症狀,因無論先前是否有精神相關病史的病人皆有可能出現此風險。 更多相關訊息與連結請參考FDA網址:https://reurl.cc/D9o6ME (全文完) 資料來源:美國FDA之藥物安全警訊 資料提供:台大醫院藥劑部